Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase)
and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at
pharmacodynamically active concentrations. This study plans to evaluate PQR309 in treatment
of patients with first progression of glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
PIQUR Therapeutics AG
Collaborators:
University Hospital Inselspital, Berne University Hospital, Basel, Switzerland University Hospital, Zürich